Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHunger persisting on Mounjaro is more common than most people expect, especially in the first few weeks of treatment. Tirzepatide reduces appetite by activating GIP and GLP-1 receptors, but the effect builds gradually as your dose increases — at 2.5mg, the starter dose, appetite suppression is typically mild. That's not a failure of the medicine; it's how the titration schedule is designed. These are prescription-only medicines, and a GPhC-registered prescriber reviews your suitability and progress at every stage.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you've started Mounjaro, you're a week in, and you're eating dinner and still reaching for more. You expected the medicine to switch off your appetite like a tap. It hasn't. You're starting to wonder whether it's working at all.
This is one of the questions our prescribers hear regularly, and the short answer is that 2.5mg is designed to let your body adjust to tirzepatide, not to produce dramatic appetite changes. The dose that tends to shift hunger noticeably for most people is somewhere between 5mg and 10mg, and the titration schedule (typically moving up every four weeks) exists for good reason: increasing too quickly raises the risk of nausea and other GI side effects. Staying at the lower dose a little longer is sometimes the right clinical call, even when it feels frustrating.
If you are on day one or day two and hunger feels unchanged, that's particularly expected. The medicine needs time to reach a steady level in your system. The experience on day one of Mounjaro is rarely representative of how you'll feel at week four. Patience at this stage is genuinely part of the process, not a workaround.
According to the NHS tirzepatide medicines page, reduced appetite is a recognised effect of tirzepatide that varies between individuals, it is not a switch that flips identically for everyone.
A different scenario: you moved up to 7.5mg or 10mg, the first few weeks felt genuinely different, and now (a fortnight into the same pen) your appetite seems to be returning. Some people describe this as the medicine "wearing off" toward the end of the week before the next injection.
This is a recognised pattern. Tirzepatide has a half-life of around five days, so drug levels do fluctuate slightly between weekly doses. If hunger reliably picks up on days six and seven, keeping your injection day consistent can help level things out. Injecting on the same day each week (a Tuesday evening after work, say) reduces the variation.
It's also worth looking at what you're eating on Mounjaro on those hungrier days. High-glycaemic foods (white bread, sugary snacks, processed carbs) are processed quickly and leave the stomach fast, which means the feeling of fullness Mounjaro supports is shorter-lived. Protein and fibre slow gastric emptying further and work with the medicine rather than against it. For readers wondering about specific foods, whether sweets are a problem on Mounjaro has a fuller answer, but the principle applies broadly: foods that spike blood sugar quickly tend to undercut the appetite effect.
If the return of hunger coincides with a stressful period, poor sleep or a shift in your activity level, those factors genuinely matter. Cortisol and disrupted sleep are independently linked to increased appetite signals, the medicine can work against them, but it's working harder.
Changing your dose or timing is a decision for your prescriber, not something to try unilaterally. What sits within your control is the framework around the medicine.
On protein: aiming for a palm-sized portion at each meal is a practical, non-obsessive target. Eggs, Greek yoghurt, fish, chicken, pulses, all slow digestion and extend satiety. The NHS Better Health guidance on healthy weight and diet gives a solid starting framework that complements GLP-1 treatment without requiring calorie obsession.
On fluids: drink water before you decide you're hungry. A glass before a meal genuinely reduces how much most people eat, and thirst mimics hunger more than most people realise, particularly on Mounjaro, where reduced nausea at higher doses can mean people feel well enough to eat more freely again.
On timing: eating more slowly and putting your fork down between bites sounds trivial, but tirzepatide slows gastric emptying, which means fullness signals arrive later than usual. Eating quickly means you can overshoot the point of satiety before you feel it. Stopping mid-meal for a minute often reveals you were already full.
If you've tried all of this and hunger remains a significant barrier, that's a clinical conversation. A prescriber can look at whether a dose review is appropriate, and whether anything in your health picture is worth exploring. Hunger on Mounjaro doesn't always mean the medicine isn't working, but persistent, unmanageable hunger at an established dose is worth raising. You can read more about the full Mounjaro treatment overview or whether Mounjaro affects calorie burn alongside appetite.
The cost of treatment is a fair question too, if you're weighing up whether continuing makes sense, the context around Mounjaro pricing in the UK is worth understanding before making any decision. At nume, every repeat order includes a clinical re-review of your progress, so persistent hunger is exactly the kind of thing our prescribers can look at properly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.